Lassa-Vesicular Stomatitis Chimeric Virus Safely Destroys Brain Tumors

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Virology

• Publication date

  2015-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.00709-15PMID 25878115PMCID PMC4468483
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.

  2015cited by this paper
• Lassa virus entry requires a trigger-induced receptor switch

  2014cited by this paper
• Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.

  2014influential reference
• Long-Distance Interferon Signaling within the Brain Blocks Virus Spread

  2014cited by this paper
• Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV

  2013cited by this paper
• LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus

  2013cited by this paper
• Deciphering the Glycosylome of Dystroglycanopathies Using Haploid Screens for Lassa Virus Entry

  2013cited by this paper
• Vesicular Stomatitis Virus Variants Selectively Infect and Kill Human Melanomas but Not Normal Melanocytes

  2013influential reference
• Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection

  2012cited by this paper
• A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.

  2012cited by this paper
• Ebola virus entry requires the host‐programmed recognition of an intracellular receptor

  2012cited by this paper
• Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

  2012cited by this paper
• Highly Attenuated Recombinant Vesicular Stomatitis Virus VSV-12′GFP Displays Immunogenic and Oncolytic Activity

  2012cited by this paper
• Treatment of Melanoma Brain Metastases: A New Paradigm

  2012cited by this paper
• Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates

  2012cited by this paper
• Niemann-Pick C1 (NPC1)/NPC1-like1 Chimeras Define Sequences Critical for NPC1’s Function as a Filovirus Entry Receptor

  2012cited by this paper
• Anterograde or retrograde transsynaptic labeling of CNS neurons with vesicular stomatitis virus vectors

  2011influential reference
• Ebola virus entry requires the cholesterol transporter Niemann-Pick C1

  2011cited by this paper
• Activating Systemic T-Cell Immunity Against Self Tumor Antigens to Support Oncolytic Virotherapy with Vesicular Stomatitis Virus

  2011cited by this paper
• Significant Protection against High-Dose Simian Immunodeficiency Virus Challenge Conferred by a New Prime-Boost Vaccine Regimen

  2011cited by this paper
• Vesicular Stomatitis Virus Has Extensive Oncolytic Activity against Human Sarcomas: Rare Resistance Is Overcome by Blocking Interferon Pathways

  2011cited by this paper
• Pseudotyping Vesicular Stomatitis Virus with Lymphocytic Choriomeningitis Virus Glycoproteins Enhances Infectivity for Glioma Cells and Minimizes Neurotropism

  2011cited by this paper
• The Length of Vesicular Stomatitis Virus Particles Dictates a Need for Actin Assembly during Clathrin-Dependent Endocytosis

  2010cited by this paper
• Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses

  2010cited by this paper
• Some Attenuated Variants of Vesicular Stomatitis Virus Show Enhanced Oncolytic Activity against Human Glioblastoma Cells relative to Normal Brain Cells

  2009cited by this paper
• Peripheral Immunization Blocks Lethal Actions of Vesicular Stomatitis Virus within the Brain

  2009cited by this paper
• Receptor binding and cell entry of Old World arenaviruses reveal novel aspects of virus-host interaction.

  2009cited by this paper
• A Forward Genetic Strategy Reveals Destabilizing Mutations in the Ebolavirus Glycoprotein That Alter Its Protease Dependence during Cell Entry

  2009cited by this paper
• Matrix protein mediated shutdown of host cell metabolism limits vesicular stomatitis virus-induced interferon-alpha responses to plasmacytoid dendritic cells.

  2008cited by this paper
• Identification of a Broad-Spectrum Arenavirus Entry Inhibitor

  2008cited by this paper
• Systemic Vesicular Stomatitis Virus Selectively Destroys Multifocal Glioma and Metastatic Carcinoma in Brain

  2008influential reference
• Attenuation of Recombinant Vesicular Stomatitis Virus-Human Immunodeficiency Virus Type 1 Vaccine Vectors by Gene Translocations and G Gene Truncation Reduces Neurovirulence and Enhances Immunogenicity in Mice

  2007cited by this paper
• Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

  2006cited by this paper
• Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates

  2006cited by this paper
• Synergistic Attenuation of Vesicular Stomatitis Virus by Combination of Specific G Gene Truncations and N Gene Translocations

  2006cited by this paper
• Variable Deficiencies in the Interferon Response Enhance Susceptibility to Vesicular Stomatitis Virus Oncolytic Actions in Glioblastoma Cells but Not in Normal Human Glial Cells

  2006cited by this paper
• Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection

  2005cited by this paper
• A Vesicular Stomatitis Virus Recombinant Expressing Granulocyte-Macrophage Colony-Stimulating Factor Induces Enhanced T-Cell Responses and Is Highly Attenuated for Replication in Animals

  2005cited by this paper
• A Single-Cycle Vaccine Vector Based on Vesicular Stomatitis Virus Can Induce Immune Responses Comparable to Those Generated by a Replication-Competent Vector

  2005cited by this paper
• Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.

  2004cited by this paper
• Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses

  2004cited by this paper
• Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier

  2004cited by this paper
• Characterization of Nonpathogenic, Live, Viral Vaccine Vectors Inducing Potent Cellular Immune Responses

  2004influential reference
• Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity

  2003cited by this paper
• Characterization of Vesicular Stomatitis Virus Recombinants That Express and Incorporate High Levels of Hepatitis C Virus Glycoproteins

  2002cited by this paper
• Relative Neurotropism of a Recombinant Rhabdovirus Expressing a Green Fluorescent Envelope Glycoprotein

  2002cited by this paper
• Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins.

  2002cited by this paper
• Epidemiology of primary brain tumors: current concepts and review of the literature.

  2002cited by this paper
• Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration.

  2001cited by this paper
• Rearrangement of the Genes of Vesicular Stomatitis Virus Eliminates Clinical Disease in the Natural Host: New Strategy for Vaccine Development

  2001cited by this paper
• New innovations and developments for glioma treatment.

  2001cited by this paper
• Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

  2000cited by this paper
• Vesicular Stomatitis Virus (VSV) Therapy of Tumors

  2000cited by this paper
• Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors

  1999cited by this paper
• The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

  1998cited by this paper
• Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

  1998cited by this paper
• Recombinant vesicular stomatitis viruses from DNA.

  1995cited by this paper
• Distribution of vesicular stomatitis virus proteins in the brains of BALB/c mice following intranasal inoculation: an immunohistochemical analysis.

  1994cited by this paper
• Intracellular distribution of input vesicular stomatitis virus proteins after uncoating

  1991cited by this paper
• Non-Lethal Infection of Aminergic Reticular Core Neurons: Age-Dependent Spread of ts Mutant Vesicular Stomatitis Virus from the Nose

  1988cited by this paper
• LSU Digital Commons LSU Digital Commons Altering the tropism of lentiviral vectors through pseudotyping Altering the tropism of lentiviral vectors through pseudotyping

  year unknowncited by this paper

• Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends

  2025cites this paper
• Latest insights into oncolytic viro-immunotherapy with vesicular stomatitis virus.

  2025cites this paper
• Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations

  2024cites this paper
• Establishment and application of a surrogate model for human Ebola virus disease in BSL-2 laboratory.

  2024cites this paper
• Arenaviruses: Old viruses present new solutions for cancer therapy

  2023cites this paper
• Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

  2023cites this paper
• Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses

  2023cites this paper
• Lassa fever and carcinogenesis: emerging as new areas of concern in clinical surgery

  2023cites this paper
• Rational selection of an ideal oncolytic virus to address current limitations in clinical translation.

  2023cites this paper
• Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?

  2022cites this paper
• Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential

  2022cites this paper
• Anthony N. van den Pol (1949–2020)

  2021cites this paper
• Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells

  2021cites this paper
• Chemogenetic ON and OFF switches for RNA virus replication

  2021cites this paper
• Replication-competent vesicular stomatitis virus vaccine vector protects against 1 SARS-CoV-2-mediated pathogenesis 2

  2020cites this paper
• Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors

  2020cites this paper
• A tool with many applications: vesicular stomatitis virus in research and medicine

  2020cites this paper
• Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis

  2020cites this paper
• Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice

  2020cites this paper
• Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers

  2020cites this paper
• Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.

  2020cites this paper
• Advancing glioblastoma treatment with oncolytic virotherapy

  2018cites this paper
• Chikungunya-vesicular stomatitis chimeric virus targets and eliminates brain tumors.

  2018cites this paper
• The emerging role of oncolytic virus therapy against cancer.

  2018cites this paper
• Oncolytic Alphaviruses in Cancer Immunotherapy

  2017cites this paper
• Replication-Competent Viral Vectors for Vaccine Delivery

  2017cites this paper
• Determinants of Organotropic Metastasis

  2017cites this paper
• Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective

  2017cites this paper
• VSV based virotherapy in ovarian cancer: the past, the present and …future?

  2017cites this paper
• Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain

  2017cites this paper
• Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models

  2017cites this paper
• Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

  2017cites this paper
• Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

  2016cites this paper
• Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy

  2016cites this paper
• Mood stabilizers inhibit cytomegalovirus infection.

  2016cites this paper
• Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson’s Disease

  2016cites this paper
• EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

  2015cites this paper